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http:WHAT THIS PAPER ADDS
Comparing these techniques identiﬁes a modest correlation but some key differences related to the spatial
distribution of 18F-FDG and USPIO uptake. This may reﬂect the differing elements of macrophage activity
detected by these modalities: glycolysis and phagocytosis. Further studies are needed to assess whether
identiﬁcation of this varying activity will inﬂuence aneurysm growth rates and the clinical outcome.Objectives: Inﬂammation is critical in the pathogenesis of abdominal aortic aneurysm (AAA) disease. Combined
18F-ﬂudeoxyglucose (18F-FDG) positron emission tomography with computed tomography (PET-CT) and ultrasmall
superparamagnetic particles of iron oxide (USPIO)-enhanced magnetic resonance imaging (MRI) are non-invasive
methods of assessing tissue inﬂammation. The aim of this study was to compare these techniques in patients
with AAA.
Materials and methods: Fifteen patients with asymptomatic AAA with diameter 46  7 mm underwent PET-CT
with 18F-FDG, and T2*-weighted MRI before and 24 hours after administration of USPIO. The PET-CT and MRI
data were then co-registered. Standardised uptake values (SUVs) were calculated to measure 18F-FDG activity,
and USPIO uptake was determined using the change in R2*. Comparisons between the techniques were made
using a quadrant analysis and a voxel-by-voxel evaluation.
Results: When all areas of the aneurysm were evaluated, there was a modest correlation between the SUV on
PET-CT and the change in R2* on USPIO-enhanced MRI (n ¼ 70,345 voxels; r ¼ .30; p < .0001). Although regions
of increased 18F-FDG and USPIO uptake co-localised on occasion, this was infrequent (kappa statistic 0.074; 95%
CI 0.026e0.122). 18F-FDG activity was commonly focused in the shoulder region whereas USPIO uptake was more
apparent in the main body of the aneurysm. Maximum SUV was lower in patients with mural USPIO uptake.
Conclusions: Both 18F-FDG PET-CT and USPIO-MRI uptake identify vascular inﬂammation associated with AAA.
Although they demonstrate a modest correlation, there are distinct differences in the pattern and distribution of
uptake, suggesting a differential detection of macrophage glycolytic and phagocytic activity respectively.
 2015 The Authors. Published by Elsevier Ltd on behalf of European Society for Vascular Surgery. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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//dx.doi.org/10.1016/j.ejvs.2015.12.018techniques. In contrast to anatomical and structural ap-
proaches, molecular and cellular imaging targets the activity
of speciﬁc biochemical and cellular processes to provide
insight into the aetiology, biology, and pathogenesis of
diseased states. Moreover, this has the potential to reﬁne
the diagnosis and risk stratiﬁcation of cardiovascular disease
as well as to assess responses to speciﬁc therapeutic in-
terventions.1e5 A combination of morphological imaging
with molecular imaging has proven a particularly useful
approach.
18F-Fludeoxyglucose (18F-FDG) is used to image meta-
bolically active cells with combined positron emission and
computed tomography (PET-CT). 18F-FDG accumulates in all
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tion to their metabolic activity. In atherosclerotic arteries
and those affected by vasculitides, 18F-FDG uptake corre-
lates with the degree of arterial inﬂammation and is
reproducible.6e8 Furthermore, 18F-FDG uptake increases
with the number of cardiovascular risk factors present, is
predictive of future cardiovascular events,9e11 and has been
used as a biomarker to demonstrate the anti-inﬂammatory
effects of statins and other novel therapies.12e14 18F-FDG
accumulates in the wall of abdominal aortic aneurysms
(AAAs) and several studies have correlated uptake with
aortic vessel wall inﬂammation on histology.15e17 There is
evidence to suggest that 18F-FDG can discriminate between
asymptomatic and symptomatic AAA, but its potential use
as a marker of aneurysm expansion, progression, and
rupture has yet to be established.15e22
Magnetic resonance imaging (MRI) with ultrasmall
superparamagnetic particles of iron oxide (USPIO) is an
alternative approach for detecting cellular inﬂamma-
tion.23,24 Owing to their small particle size (diameter 10e
30 nm), USPIO escape immediate recognition by the
reticulo-endothelial system, persist in the bloodstream, and
accumulate at sites of vascular inﬂammation. Here they
undergo phagocytosis by tissue-resident macrophages
within which they accumulate and are detectable on T2-
and T2*-weighted MRI sequences. Within atheromatous
plaques, USPIO uptake correlates with macrophage density,
distinguishes stable from unstable carotid plaques, and is
reduced following high-dose atorvastatin therapy.25e27
USPIO uptake in the wall of AAAs has previously been
demonstrated, where it co-localises with macrophages and
is associated with a threefold higher AAA growth rate.24
Given that both 18F-FDG PET and USPIO-enhanced MRI
have been used to assess vascular inﬂammation in patients
with AAA, the aim of this study was to compare 18F-FDG PET
and USPIO-enhanced MRI in patients with AAAs. Specif-
ically, the spatial distribution and intensity of the inﬂam-
matory process using both techniques was assessed to
determine whether they provided complementary or
distinct insights into the pathology of AAAs.
MATERIALS AND METHODS
Subjects
Patients with asymptomatic AAA (diameter 30e55 mm on
duplex ultrasound examination) were recruited from the
aneurysm surveillance clinic at the Royal Inﬁrmary of
Edinburgh. Exclusion criteria were age < 50 years, active
systemic inﬂammatory or malignant disease, renal
dysfunction (estimated glomerular ﬁltration rate < 30 mL/
min, because of the risks of contrast induced renal
dysfunction), hepatic cirrhosis (ChildePugh score B or C,
because of the contrast agent not having been studied in
this group of patients), planned AAA surgery within 6
months of screening, any contraindication to MRI and
insulin-dependent diabetes mellitus (due to the confound-
ing of 18F-FDG uptake with variable blood glucose concen-
trations). Studies were performed with the approval of thelocal research ethics committee, in accordance with the
Declaration of Helsinki, and with the written informed
consent of each participant.
All patients underwent a comprehensive baseline clinical
assessment, including evaluation of their cardiovascular risk
factor proﬁle and recording of an abdominal ultrasound
scan. 18F-FDG PET-CT and USPIO-MRI data acquisition pro-
cedures are detailed in Methods I of the Supplementary
Material.Image analysis
Registration of PET and MRI images. The accuracy of PET-CT
to Computed Tomography Aortogram (CTA) registration was
conﬁrmed by visual assessment, and minor intra-scan pa-
tient movement was corrected using a semi-automatic rigid
3D voxel registration protocol (Analyze 11.0, Mayo Clinic,
Rochester, MN, USA). Registration of the MRI data allowed
the excellent anatomical detail on the T2W images and the
high sensitivity of T2*W images for iron to be utilised. All
MR images were registered to the pre-contrast T2W image.
The CTA and T2W MRI datasets were also co-registered. At
the end of the registration process, the pre-USPIO T2*W
MRI, the post-USPIO T2*W MRI, the CTA, and the PET-CT
were all co-registered to enable direct comparison. All
steps of registration used a semi-automatic rigid 3D voxel
registration protocol that has been previously validated and
published.24 All outputs were manually checked and opti-
mised as necessary. Two independent trained observers,
who were experienced vascular surgeons who had devel-
oped the image analysis techniques, undertook the ana-
lyses. There was excellent inter-observer agreement with
kappa statistics between 0.84 and 0.89, for all steps.
18F-FDG quantiﬁcation. The maximum standardised uptake
value (SUVmax) was used to assess
18F-FDG uptake in the
aneurysm. The SUV is the decay-corrected tissue uptake
divided by the injected dose per unit body weight and is a
semi-quantitative dimensionless unit that has been previ-
ously validated and is a commonly used measure of tissue
18F-FDG uptake.5,28 The SUV in vascular structures can be
heavily inﬂuenced by variability of 18F-FDG activity in the
blood pool. Therefore, the tissue-to-background ratio (TBR)
was also calculated by dividing the tissue SUVmax by an
averaged mean SUV in the blood pool, derived from ﬁve
circular regions of interest in the centre of the inferior vena
cava. An area of 18F-FDG uptake was deﬁned as positive if
the SUVmax or TBR was > 125% of the value obtained from
an averaged SUVmax from ﬁve randomly selected regions in
the non-aneurysmal descending thoracic aorta.29,30
USPIO quantiﬁcation. Using validated in-house software
built in the Matlab environment (Mathworks, Natick, MA,
USA), all four echoes in the multi-echo T2*W sequence
were combined to generate a T2* map in which the
magnitude of each voxel represented the T2* value
(S(t) ¼ S(0)exp  (t/T2*). USPIO uptake was detected using
the change in T2* (or R2*; R2* ¼ 1/T2*) following USPIO
administration. We applied a validated image analysis
Table 1. Baseline characteristics of patients with abdominal aortic
aneurysm (n ¼ 15).
Age (years) 73  4
Male:female 13:2
% Male 87%
Maximum anteroposterior
diameter of AAA (mm)
46
(range 34e55)
Cardiovascular history
Coronary artery disease 5 (33%)
Stroke or transient ischemic attack 2 (13%)
Peripheral vascular disease 2 (13%)
Risk factors
Current smoking habit 6 (40%)
Previous smoking habit 8 (60%)
Diabetes mellitus 1 (7%)
Hypertension 10 (67%)
Hypercholesterolemia 15 (100%)
Medications
Antiplatelet agent 12 (80%)
Statin 13 (87%)
b-Blocker 6 (40%)
ACE inhibitor/ARBa 8 (53%)
Other Anti-hypertensive 2 (13%)
a Angiotensin converting enzyme (ACE) inhibitor or angiotensin II
receptor blocker (ARB).
520 O.M.B. McBride et al.method previously published for DT2* thresholding of AAA-
USPIO data in order to visually interpret and threshold the
UPSIO T2*-weighted data.24 Increasingly R2* (¼1/T2*) are
reported to provide a positive correlation between con-
centration of USPIO and increase in R2* values, facilitating
more straightforward data interpretation and visualisation.
Detailed USPIO quantiﬁcation methodology is outlined in
Methods II of the Supplementary Material.
The correlation between 18F-FDG uptake and USPIO dis-
tribution was analysed using three methods: the signals in
different regions of the aneurysm were compared by
drawing regions of interest (ROI) around the wall and
thrombus, then the co-localisation across the aneurysm as a
whole using a voxel-by-voxel analysis was studied. Finally, a
previously deﬁned aneurysm classiﬁcation system based on
USPIO uptake on MRI24 was compared with the mean
SUVmax and TBR for the positive regions of
18F-FDG uptake
in each aneurysm.
Colour maps. Two independent observers, blinded to pa-
tient demographics and aneurysm size reviewed the DT2*
colour maps and the fused PET-CT data. Each axial slice was
divided into quadrants and each quadrant was deﬁned as
positive if it included at least one region of increased USPIO
or 18F-FDG uptake, or negative if it did not. On the DT2*
colour maps, signiﬁcant regions of USPIO accumulation
were deﬁned as consisting of at least 10 contiguous voxels
with DT2* above the threshold of 59%.24 On the PET-CT
scans, ROI were drawn around areas of maximum uptake
in the wall and thrombus of the aneurysm and deﬁned as
positive if the SUVmax or TBR was > 125% of the value
obtained from an averaged SUVmax from ﬁve randomly
selected regions in the non-aneurysmal descending thoracic
aorta.
In order to deﬁne the area of the aneurysm where there
was increased uptake of USPIO or 18F-FDG, the aneurysm
was divided in the axial plane into three distinct regions: on
MRI the shoulder region extended one slice (5 mm) above
and below the point at which the aorta last measured 
30 mm in diameter, whereas on PET-CT, two slices (6 mm)
were considered. The bifurcation region was deﬁned in an
identical way but from the point where the aneurysm
reduced in diameter to  30 mm. The area between these
two points was deﬁned as the main body of the aneurysm.
Voxel-by-voxel analysis. The MR images were reconstructed
by down-sampling to achieve equivalent voxel sizes with the
corresponding PET images. A ROI encompassing the entire
aortic wall and thrombus was drawn on each slice of the
pre-contrast T2W image. These ROIs were then applied to
the PET images and to the calculated DR2* colour maps.
This enabled a quantitative voxel-by-voxel analysis of USPIO
and 18F-FDG uptake.
Aneurysm classiﬁcation. We have previously shown that
mural USPIO uptake predicts expansion; therefore, aneu-
rysms were classiﬁed into three predeﬁned groups by two
independent blinded observers: Group 1, no mural or
thrombus USPIO uptake, except for isolated periluminalenhancement; Group 2, diffuse USPIO uptake, distinct from
the periluminal thrombus and aortic wall; and Group 3 focal
areas (with at least 10 contiguous voxels) of USPIO uptake
within the aortic wall of the aneurysm, distinct from the
periluminal area and thrombus.24 PET activity in regions of
increased uptake was then compared across these three
groups.
A schematic outlining the image analysis techniques un-
dertaken can be found in Methods III of the Supplementary
Material.
Statistical analysis
Normally distributed continuous variables were expressed
as mean  standard deviation. Non-parametric data were
presented as median with interquartile ranges. Correlations
between normally distributed data were performed using
Pearson’s correlation. Comparisons were undertaken with
paired or unpaired Student’s t-tests as appropriate. A two-
sided p < .05 was regarded as statistically signiﬁcant. Sta-
tistical analysis was performed with the use of Graph Pad
Prism version 5 (GraphPad Software Inc., La Jolla, CA USA).
RESULTS
Fifteen predominantly elderly men with multiple cardio-
vascular risk factors and a mean AAA diameter of 46 mm
(range 34e55 mm) participated in the study (Table 1). All
patients were asymptomatic and had fusiform aneurysms
conﬁned to the abdominal aorta. 18F-FDG PET-CT and
USPIO-enhanced MRI scans were performed a median of 7
days apart. PET imaging of the abdomen was undertaken a
median of 92 (IQR, 89e97) minutes after injection of
237  16 MBq of 18F-FDG. The effective radiation from
participation in the study was 10.8 mSv using a conversion
Positron Emission Tomography and Magnetic Resonance Imaging 521factor of 0.014 mSv/mGy cm. The administration of 18F-FDG
and USPIO was well tolerated with no adverse events.18F-FDG uptake
Increased 18F-FDG uptake was observed within the wall of
13 of the 15 AAAs. In total there were 42 regions of
increased uptake and all were diffuse and involved the wall.
Although it was not possible to resolve whether this uptake
localised to the aneurysm wall or the thrombus, the ma-
jority were observed in the shoulder region of the aneurysm
(25/42, 60%), with a third (14/42) occurring within the main
body of the aneurysm and the remainder in close proximity
to the bifurcation (3/42). There was increased uptake in the
peri-luminal zone of the thrombus in all patients.USPIO uptake
All AAA demonstrated uptake of USPIO but focal areas of
mural USPIO were primarily conﬁned to the main body of
the aneurysm (146/271, 54%), with 28% (75/271) located in
the shoulder region and 19% (50/271) adjacent to the
bifurcation (Table 2). In keeping with our previous study,24
all patients had USPIO uptake in the periluminal area,
representing a movement of particles directly into the
thrombus from the blood pool.Comparison between 18F-FDG and USPIO uptake
When all areas of the aneurysm were considered, there was
a modest correlation between the SUV on PET-CT and the
absolute change in R2* on MRI (r ¼ .30; 95% CI 0.29e0.31,
p < .0001; Fig. 1).
In general, the main thrombus (excluding the peri-luminal
region) did not uptake 18F-FDG or USPIO. In contrast, local
inﬂammation within the wall was readily identiﬁable but
was not reﬂected by a change in T2* or R2* value in the
whole aneurysm because of the associated dilutional effect
of the thrombus.
Classiﬁcation of AAA according to 18F-FDG or USPIO up-
take using the quadrant technique was consistent and
reproducible with excellent inter-observer agreement and a
kappa statistic of 0.87 for 18F-FDG and 0.85 for USPIO. On
occasion, areas of increased USPIO and 18F-FDG uptake co-
localised to the same quadrant in the aortic wall, although
regions of USPIO uptake without corresponding 18F-FDG
uptake were also commonly seen (Fig. 2). Overall, co-Table 2. Qualitative evaluation of 18F-ﬂudeoxyglucose (FDG) uptake on
compared to ultrasmall superparamagnetic particles of iron oxide (US
18F-FDG PET-CT
Spatial resolution 4e6 mm
Periluminal enhancement Present
Region of uptake Predilection for shoulder region
Deﬁnition of uptake > 125% of the averaged SUVmax from
randomly selected regions in the non-a
descending thoracic aorta
Functional assessment Glycolytic activity
Ionising radiation Yeslocalisation of areas of increased USPIO and 18F-FDG up-
take were poor (kappa statistic 0.074; 95% CI 0.026e0.122)
and there were more areas of increased uptake identiﬁed
on MRI than on PET-CT (Table 3). Focal and discrete uptake
of USPIO can be readily discerned on MRI, whereas there
was more diffuse and ill-deﬁned uptake of 18F-FDG involving
both the wall and the thrombus on PET-CT.
Based on USPIO uptake, four patients were classiﬁed into
Group 3 and 11 into Groups 1 and 2. SUVmax and TBR
appeared to be lower in those classiﬁed as Group 3 than in
those in Groups 1 and 2, but this did not reach statistical
signiﬁcance (p ¼ .7884, 95% CI e2.181 to 1.690; Fig. 1).
There was no correlation between the grouping classiﬁca-
tion and the maximum absolute change in R2* (p ¼ .4123,
95% CI e86.99 to 37.98).DISCUSSION
In comparing 18F-FDG PET-CT with USPIO-enhanced MRI in
patients with AAA, we have identiﬁed a modest correlation
between these two imaging modalities but a number of key
differences. In particular, activity detected with these two
techniques appears to be concentrated in different regions
of the aneurysm: largely in the shoulder region with 18F-
FDG and in the body of the aneurysm using USPIO. We
believe that this reﬂects the different elements of inﬂam-
matory activity detected by these two approaches, with
PET-CT providing information related to glycolysis and
USPIO information on phagocytosis. Further studies are
now required to assess which modality will have the
greatest predictive power to determine aneurysm growth
and clinical outcome.
Inﬂammatory cells have a key role in the development
and progression of abdominal aortic aneurysms.17 Histo-
pathologically, the aneurysmal aortic wall is characterised
by focal medial neovascularisation, inﬁltration of inﬂam-
matory cells (principally macrophages and lymphocytes),
and fragmentation of elastin and collagen ﬁbres within the
extracellular matrix. Both 18F-FDG and USPIO imaging aim
to detect and quantify the inﬂammatory cellular component
and it is therefore encouraging that a modest correlation
between these two measures was observed in this study,
conﬁrming that ultimately both identify vascular inﬂam-
mation, albeit through differing pathways.
Vascular inﬂammatory cells are metabolically active and
take up 18F-FDG in an insulin-insensitive manner. Therefore,positron emission tomography and computed tomography (PET-CT)
PIO) uptake on magnetic resonance imaging (MRI).
USPIO MRI
2 mm (subject to ﬁeld of view)
Present
Predilection for main body of aneurysm
ﬁve
neurysmal
10 contiguous voxels with % change in T2* 59%
Phagocytic activity
No
Figure 1. (A.) Comparison of standard uptake value (SUV) and absolute change in R2* in the wall of the abdominal aortic aneurysm (AAA).
When the thrombus and wall of the aneurysm are considered there is a modest correlation between the SUV and the absolute change in
R2* (r ¼ 0.30). (B) MRI group classiﬁcation compared to maximum SUV (SUVmax) and tissue-to-background ratio (TBR) in the wall of the
AAA. There was no signiﬁcant difference between the SUVmax (p ¼ .4696, 95% CI e1.682 to 0.8194) or TBR (p ¼ .7884, 95% CI e2.181 to
1.690) of patients in Groups 1 and 2 and those in Group 3.
522 O.M.B. McBride et al.18F-FDG uptake in the fasted state has been proposed as a
marker of risk for aneurysm progression and rupture with
higher uptake associated with inﬂammation, aortic wall
instability, and clinical symptoms.15,18 However, the role of
18F-FDG PET-CT in AAA disease remains controversial.
Recent data have suggested that vascular 18F-FDG activity
may relate to more than simply macrophage burden,31 with
several studies identifying high lymphocyte counts and
leucocytes15,17,32 within the aortic wall and implicating
hypoxia as an important driver to 18F-FDG uptake.33
Furthermore, although several small studies have demon-
strated the ability of 18F-FDG to discriminate between
symptomatic and asymptomatic AAA,15e18,21 a number of
published studies have failed to verify these observations.Palombo et al.34 showed 18F-FDG uptake was low in
asymptomatic AAAs, with a diameter close to surgical in-
dications (mean diameter, 4.9 cm), perhaps reﬂecting
decreased cell density in large AAAs. Tegler et al.32 found no
relationship between 18F-FDG uptake and asymptomatic
(small or large) AAAs versus controls and no correlation
between histology and uptake. Similarly, Kotze et al.20 found
an inverse relationship between 18F-FDG uptake and future
growth rate of AAA.
USPIO-enhanced MRI has been used to explore a number
of inﬂammatory conditions, including atherosclerotic pla-
ques and abdominal aortic aneurysms.23e25,27 USPIO are
taken up by inﬂammatory phagocytic cells, particularly
macrophages, and accumulate at sites of cellular
Figure 2. (A,B) Representative magnetic resonance imaging (MRI) (A) and fused positron emission tomography and computed tomography
(PET-CT) (B) scans from the same patient with an abdominal aortic aneurysm (AAA). Ultrasmall superparamagnetic particles of iron oxide
(USPIO) uptake, deﬁned by percentage change in T2* is demonstrated using a colour scale. Changes in T2* value over the threshold (59%)
are presented on a graduated (yellow-red) colour scale and data below the threshold appears blue. Corresponding 18F-ﬂudeoxyglucose
(FDG) activity (red arrow) can be seen in B. Differences in the location of regions of uptake between the techniques are apparent, as
marked by the white arrow. (C,D) are corresponding MRI and fused PET-CT slices from the same patient who has no USPIO or 18F-FDG
uptake in the wall of the AAA, with uptake limited to the peri-luminal area.
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changes on MRI. In addition, histological examination of
excised tissue, including aneurysm tissue, has conﬁrmed the
co-localisation and uptake of USPIO in areas of macrophage
inﬁltration.24,35e37
We speculate that USPIO and 18F-FDG uptake represent
distinct markers of vascular inﬂammation that correspond
to differing inﬂammatory and macrophage activities.
Clearly, USPIO uptake is a measure of ongoing phagocyticTable 3. Quadrant analysis of the aneurysm wall: Regions of
uptake identiﬁed by magnetic resonance imaging (MRI) and
positron emission tomography and computed tomography (PET-
CT). kappa statistic ¼ 0.074 (95% C.I. 0.026e0.122), representing
a poor strength of agreement.activity of tissue-resident macrophages and potentially
neutrophils, whereas 18F-FDG reﬂects glucose utilisation by
cells with high metabolic requirements including the cells
implicated in vascular inﬂammation.38 Moreover there is
evidence that the two techniques target different macro-
phage subsets. Macrophages exist in varying polarised
states and have different roles in vascular tissue. M1 mac-
rophages are considered more destructive, promoting the
destabilisation and rupture of atherosclerotic plaques,
whereas phagocytosis is more important in the role of M2
macrophages stimulating reparative processes, mediated by
the production of anti-inﬂammatory cytokines and the
suppression of pro-inﬂammatory signalling.39 It has been
suggested that 18F-FDG and USPIO uptake may be able to
differentiate these two distinct M1 and M2 macrophage
sub-populations respectively.40 In this study, the majority of
18F-FDG uptake was identiﬁed in the shoulder region of the
aneurysm, an area of high biomechanical stress,41,42 with a
particular tendency to rupture: perhaps related to a
destructive macrophage phenotype in this area.
Even though it has been demonstrated that our USPIO
aneurysm classiﬁcation identiﬁes aneurysms likely to prog-
ress and dilate (Group 3; distinct mural USPIO uptake) we
found no correlation between this classiﬁcation and 18F-
FDG uptake nor the maximum absolute change in R2*. This
supports the suggestion that it is the location of USPIO
524 O.M.B. McBride et al.uptake that is crucial, rather than the degree of USPIO
uptake. However, the modest correlation that was demon-
strated between maximum absolute change in R2* and SUV
on a voxel-by-voxel basis supports the contention that these
imaging modalities are both detecting elements of macro-
phage activity, namely phagocytosis and glucose
metabolism.Study limitations
There are important study limitations and technical con-
siderations when interpreting our ﬁndings.We acknowledge
that co-registration of the MRI and PET-CT datasets was
challenging and cannot exclude partial or incomplete co-
registration. Moreover, the limited in-plane resolution of
PET-CT makes deﬁnition of the aortic wall and thrombus
difﬁcult and therefore challenging to locate the exact site of
activity. Indeed this may also explain the increased 18F-FDG
uptake observed in the shoulder region, which is more
prone to partial volume effects due to its angulation
through the slice. This may reduce the sensitivity of the
study in detecting 18F-FDG or USPIO activity. However, as
the thrombus uptakes little contrast agent, if thrombus was
inadvertently included in the aortic wall assessment, this
would lead to a tendency to under report uptake, thus our
ﬁndings could be considered conservative. Additionally,
there is no consensus or validated deﬁnition of quantitative
signiﬁcance values for 18F-FDG or USPIO uptake and despite
the excellent inter-observer reproducibility demonstrated in
this study, this may contribute to the differences observed.
The contribution of statin therapy to the results of this
study also cannot be excluded. To date there is only
observational data showing AAA growth reduction with
statins and mechanistic data are limited.43,44 Although
statin use has been shown to suppress AAA formation in
animal models, this has not been translated to humans.45,46
The use of statins in vascular patients to reduce cerebro-
vascular and cardiovascular mortality as well as in patients
undergoing AAA surgery is well documented.47,48 Conse-
quently a clinical trial with and without statin therapy in
AAA patients would be ethically challenging. The clinical
trial was registered at ClinicalTrials.gov (NCT01749280)
Intra-individual correlation of histologic specimens from
areas of minimum and maximum uptake of contrast would
provide evidence of co-localisation of inﬂammatory activity
but the practicalities of such are limited with the increase in
endovascular abdominal aortic aneurysm repair (EVAR) and
the ability to sample only tissue from the anterior portion
of the aortic wall. Moreover, ex vivo 18F-FDG uptake is
limited by the need for fresh viable tissue, whereas USPIO
uptake can only be assessed when undertaken in very close
proximity to elective surgery.
This was a small study population that will require pro-
spective evaluation in larger patient cohorts. Furthermore,
this study was limited by the exclusion of AAA  55 mm as
aneurysm growth and rupture is unpredictable and non-
linear. Current guidelines suggest that surveillance with
selective repair is the most appropriate managementstrategy.49 However, as improvements in device technology
for EVAR continues, this may change. Given this limited
sample size, we were unable to assess the relationship
between uptake of either 18F-FDG or USPIO with AAA
growth rates or clinical outcome. A number of small studies
have demonstrated the ability of 18F-FDG to differentiate
between symptomatic and asymptomatic AAAs15e18,21 and
a recent study has suggested an association between 18F-
FDG activity and future clinical events.41 A pilot study of 29
patients demonstrated that USPIO uptake in the wall of AAA
is associated with accelerated expansion rates.24 Further
datasets with long-term follow-up are therefore required to
undertake more complete evaluation of these promising
imaging approaches.
An observational surveillance trial is currently underway
at the centre to assess the relationship between mural
USPIO uptake and subsequent clinical outcomes, with the
aim of improving risk stratiﬁcation of patients with AAA: the
MA3RS trial (MRI for AAA to predict rupture or surgery;
ISRCTN76413758).
In conclusion, the correlation between 18F-FDG PET-CT
and USPIO-enhanced MRI to detect vascular inﬂammation
in AAAs is modest and reﬂects the differing elements of
macrophage activity that they detect: glycolysis and
phagocytosis respectively. Whether the identiﬁcation of this
varying activity will impact on aneurysm growth rates or risk
of aneurysm rupture will require larger longitudinal study.
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